These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 668735)

  • 41. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Surgery and immunotherapy in renal cell carcinoma involving inferior vena cava.
    Valvo JR; Cos LR; Altebarmakian VK; Khuri FJ; Cockett AT
    Urology; 1982 Oct; 20(4):359-64. PubMed ID: 6183811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney.
    Morales A; Eidinger D
    J Urol; 1976 Apr; 115(4):377-80. PubMed ID: 1263310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy of renal cell carcinoma.
    deKernion JB
    Prog Clin Biol Res; 1984; 153():409-21. PubMed ID: 6206509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current status of immunotherapy in stage IV renal adenocarcinoma.
    Klotz SD; Sweeney MJ
    J Fla Med Assoc; 1983 Jan; 70(1):39-42. PubMed ID: 6827244
    [No Abstract]   [Full Text] [Related]  

  • 46. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of renal carcinoma.
    Whitehead ED
    N Y State J Med; 1981 May; 81(6):911-4. PubMed ID: 6785679
    [No Abstract]   [Full Text] [Related]  

  • 48. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
    Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
    J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjunctive treatment of renal cell carcinoma.
    Pontes JE
    Int Adv Surg Oncol; 1983; 6():309-22. PubMed ID: 6874085
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma.
    Zhang CH; Huang Y
    Asian Pac J Cancer Prev; 2016; 17(4):2027-30. PubMed ID: 27221890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
    Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial.
    Morales A; Wilson JL; Pater JL; Loeb M
    J Urol; 1982 Feb; 127(2):230-5. PubMed ID: 7038142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term results of endovascular treatment of metastatic renal cell cancer].
    Granov AM; Gorelov AI; Shumskiĭ IA; Polikarpov AA; Shkol'nik MI; Vorob'ev MI; Karelin MI
    Vestn Rentgenol Radiol; 1999; (6):20-3. PubMed ID: 10714226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.
    Zisman A; Wieder JA; Pantuck AJ; Chao DH; Dorey F; Said JW; Gitlitz BJ; deKernion JB; Figlin RA; Belldegrun AS
    J Urol; 2003 Mar; 169(3):909-16. PubMed ID: 12576811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
    Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
    Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.
    Han KR; Pantuck AJ; Bui MH; Shvarts O; Freitas DG; Zisman A; Leibovich BC; Dorey FJ; Gitlitz BJ; Figlin RA; Belldegrun AS
    Urology; 2003 Feb; 61(2):314-9. PubMed ID: 12597937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypernephroma--natural history and the influence of immunotherapy.
    deKernion JB
    Proc Inst Med Chic; 1977; 31(5):153. PubMed ID: 918061
    [No Abstract]   [Full Text] [Related]  

  • 58. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Renal cell carcinoma with colon metastases: an infrequent site for metastases].
    Valdespino-Castillo VE; Ruiz-Jaime A
    Cir Cir; 2008; 76(4):339-42. PubMed ID: 18778546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy of a murine renal cancer.
    Huben RP; Connelly R; Goldrosen MH; Murphy GP; Pontes JE
    J Urol; 1983 May; 129(5):1075-8. PubMed ID: 6854757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.